ReviewBiology2025
Unlocking New Horizons: Antibody-Drug Conjugates in Small Cell Lung Cancer.
Review in Biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Antibody-drug conjugates (ADCs), an emerging class of antitumor agents, have revolutionised the therapeutic landscape in oncology by integrating the cytotoxic efficacy of chemotherapy with the precision of targeted therapy. These agents have also demonstrated considerable potential in the treatment of small cell lung cancer (SCLC). Numerous clinical trials evaluating ADCs in SCLC are currently underway. Although encouraging outcomes have been observed, several challenges persist, including drug resistance, treatment-related toxicities, and the identification of suitable biomarkers for patient selection. A comprehensive understanding of the mechanisms underlying ADCs, along with a systematic review of their clinical development in SCLC, may provide valuable insights and strategies to address these issues. In this review, we elucidate the structure and mechanisms of action of ADCs, summarise key clinical trials in SCLC, discuss existing challenges, and suggest future directions to facilitate the advancement and clinical application of ADC-based therapies for SCLC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.